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Obtaining diffraction-quality crystals has long been a bottle-
neck in solving the three-dimensional structures of proteins.
Often proteins may be stabilized when they are complexed
with a substrate, nucleic acid, cofactor or small molecule.
These ligands, on the other hand, have the potential to induce
signiﬁcant conformational changes to the protein and ab initio
screening may be required to ﬁnd a new crystal form. This
paper presents an overview of strategies in the following areas
for obtaining crystals of protein–ligand complexes: (i) co-
expression of the protein with the ligands of interest, (ii) use of
the ligands during protein puriﬁcation, (iii) cocrystallization
and (iv) soaks.
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1. Introduction
One of the ﬁrst questions that arises when we tackle the
problem of growing crystals of protein–ligand complexes is
‘when do we add the ligand to the protein?’ Adding the ligand
during protein expression may enable us to obtain soluble
protein. If the ligand is added during certain steps of protein
puriﬁcation, during the entire protein puriﬁcation or during
the ﬁnal concentration, the protein may be stabilized and
aggregation problems lessened or eliminated. If the protein is
stable, is it better to cocrystallize the ligand with the puriﬁed
protein? In instances where protein supply is limited, can we
soak the ligands into pre-existing crystals without disrupting
the crystal lattices and destroying the crystals? It is impossible
to predict which route will be successful, so systematic testing
is required to determine which method will work best for your
crystals.
2. Co-expression with ligands of interest
When the protein is expressed with ligands of interest, we
have seen increased levels of protein expression and increased
amounts of soluble protein. These are often dependent upon
the ligand, the potency of the ligand, the solubility of the
ligand and the DMSO concentrations used and compound
availability. In several cases, the introduction of additional
mutations signiﬁcantly affected the protein expression in the
presence of ligands.
Obtaining sufﬁcient quantities of puriﬁed steroid nuclear
receptor ligand-binding domain (LBD) was critical for the
eventual structure determination of progesterone receptor
(PR), androgen receptor (AR), glucocorticoid receptor (GR)
and mineralocorticoid receptor (MR). In all of these cases, co-expression with a high-afﬁnity ligand was key to obtaining
protein for structural studies (Williams & Sigler, 1998; Matias
et al., 2000; Sack et al., 2001; He et al., 2004; Madauss et al.,
2004; Fig. 1).
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Figure 3
Effect of ligand on GR LBD expression. The red arrow denotes GR LBD
expressed with seven different ligands. In some cases, the addition of a
methyl group to the ligand could make the difference in increased
expression levels.
Figure 1
Androgen receptor. Incorporation of a high-afﬁnity ligand during protein
expression led to a system that routinely gives sub-2 A ˚ structures (He et
al., 2004).
Figure 4
GR LBD complexed with a ligand. Growth of diffraction-quality GR
crystals depended on the presence of a high-afﬁnity ligand during protein
expression, the F602S mutation and the type of ligand.
Figure 2
Effect of the F602S mutation on GR expression. Comparison of the
protein expression of wild-type GR (lane 1) and F602S GR (lane 2) in the
presence of 10 mM dexamethasone. The proteins shown are the soluble
fractions from the Ni
2+ column. Lanes 3–5 show the puriﬁcation of the
F602S LBD (lane 3, sample after thrombin digestion; lane 4, Ni
2+ column
ﬂowthrough of the thrombin-digested material; lane 5, ﬁnal puriﬁed
protein; Bledsoe et al., 2002).
Figure 5
Effect of the C808S mutation and ligand type on MR expression.
Although the C808S mutation is equivalent to the GR F602S mutation, it
has a more pronounced effect on GST-MR LBD expression. This
mutation produced increased expression of MR in the presence of a
variety of ligands (L1, ligand 1; L2, ligand 2; L3, ligand 3). High levels of
protein expression still require the presence of ligand during cell growth.
Figure 6
Mineralocorticoid receptor. The MR C808S mutant expressed well in the
presence of potent compounds and its structure has been determined in
complex with several ligands (Bledsoe et al., 2005).These techniques were still not sufﬁcient to provide soluble
protein for the recalcitrant nuclear receptors GR and MR.
Expression studies with GR demonstrated that mutating the
phenylalanine at position 602 to a serine residue (F602S), as in
PR, led to increased expression of this receptor (Bledsoe et al.,
2002; Fig. 2).
Although expression of soluble GR LBD increased with the
F602S mutation, further investigations revealed that the
ligand type had a dramatic effect on the expression levels
(Fig. 3).
A multi-faceted approach of expression as a GST fusion,
the presence of high-afﬁnity ligands during cell growth,
isolation under denaturing conditions, the F602S mutation and
optimization of ligand type led to the growth of GR crystals
and subsequent structure determinations (Bledsoe et al., 2002;
Fig. 4).
In similar expression studies with MR, the equivalent
residue, Cys808, was also mutated to serine (C808S), produ-
cing an even more dramatic increase in expression of soluble
GST MR LBD in Escherichia coli (Bledsoe et al., 2005; Figs. 5
and 6).
Since the expression of these nuclear receptors is normally
ligand-dependent, what strategy can one use if one is unableto
express protein with an important ligand? In such an instance
with PR, the protein was expressed in the presence of a low-
afﬁnity ligand (50 nM). During the cell lysis, protein puriﬁ-
cation, dialysis and ﬁnal concentration, a higher afﬁnity ligand
of interest (5–10 nM) was included in molar excess. This was
the only method by which crystals of the ligand of interest
were grown (Fig. 7).
3. Use of ligands during protein purification
If you have optimized your system for protein expression, but
the protein is not well behaved, the use of ligands during the
protein puriﬁcation may be a useful avenue to pursue. When
ligands are included during the cell lysis, during part of or the
entire puriﬁcation process or are added during refolding,
improvements in stability, solubility and aggregation have
been observed. In some instances, the ligands have displaced
other proteins, e.g. HSP90.
In one example, a recombinant enzyme (kinase 1) from a
baculovirus was expressed in insect cells. The cell lysate was
subjected to immobilized metal-afﬁnity chromatography
(IMAC) and size-exclusion chromatography (SEC). Fig. 8(a)
shows a typical SEC chromatogram for this enzyme. All the
protein elutes at 700 ml (the void volume for this column). The
enzyme preparation is highly contaminated with other
proteins and likely nucleic acids (given the high absorbance at
260 nm). Although this enzyme is active, it is unsuitable for
structural studies. In an effort to prepare enzyme for X-ray
diffraction studies, an inhibitor speciﬁc for the recombinant
enzyme was included in the lysis and chromatography buffers.
Fig.8(b) is the SEC (size-exclusion chromatography) proﬁleof
the enzyme plus inhibitor. The proteins eluting at the 700 ml
void are the same as seen in Fig. 8(a), but eluting at about
950 ml (the position expected for monomeric enzyme) is
enzyme that is homogenous. The enzyme puriﬁed in the
presence of inhibitor was successfully crystallized, enabling
the three-dimensional structure to be determined.
Addition of the ligand during the cell-lysis step and
throughout the entire protein-puriﬁcation process was the key
to obtaining pure monomeric kinase 1 (Fig. 8b). If no ligand
was included, the resulting peak was a mixture of protein,
DNA and lipids (Fig. 8a). Crystals grown from the pure
monomeric protein routinely diffracted to 2–2.3 A ˚ (Fig. 9).
Pure estrogen receptor  was obtained when the cells were
lysed in the presence of urea and subsequently puriﬁed by
estradiol afﬁnity chromatography. The key to obtaining well
behaved protein was refolding this protein in the presence of a
ligand. This gave sufﬁcient quantities of soluble protein
without special growth conditions, i.e. inclusion of the ligand
during protein expression (Brzozowski et al., 1997; Tanen-
baum et al., 1998).
Work is still in progress on kinase 2, which copuriﬁes with
HSP90 on all chromatography media tested to date. We were
not able to disrupt the kinase 2–HSP90 complex by the
addition of a variety of salts, detergents or ATP. However,
once a high-afﬁnity ligand was included during the early steps
of the puriﬁcation, we obtained soluble kinase 2 without the
HSP90. Although we do not yet have crystals of this protein,
we now have monomeric protein to use for crystallization
trials.
4. Cocrystallization
One of the common methods of obtaining crystals of a
protein–ligand complex is cocrystallization, where the ligand is
added to the protein to form a complex that is subsequently
used in crystallization trials. This is often the method of choice
when the compounds are quite insoluble or the protein
aggregates easily. Cocrystallization is affected by temperature,
protein concentration, ligand concentration, the use of addi-
tives to improve ligand binding, ligand exchange prior to
cocrystallization and cross-seeding. A special type of cocrys-
tallization, real time in situ competition crystallization
(RTISCC), may also be employed.
4.1. Temperature
4.1.1. Temperature changes when complexing the protein
and ligand. Often we complex our protein with the ligand of
interest and incubate at 277 K for 30 min to 1 h before setting
up the crystallization screens. If the ligand is rather insoluble,
changing the temperature of this incubation may facilitate
complex formation. Cocrystals of kinase 3 were obtained only
when the protein–ligand mixture was incubated at room
temperature for 30–60 min (Fig. 10). The samples were then
transferred to ice immediately prior to setting up the crystal-
lization screens.
4.1.2. Heat treatment of the protein–ligand complex/use of
additives. We often have a protein that does not crystallize or
gives poorly diffracting crystals. One quick experiment
requiring minimal equipment that can be performed to see if
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This can reduce or eliminate protein that is not folded prop-
erly, giving a more homogeneous protein sample. A time-
course study can easily be performed to determine the most
effective temperature and time for the heat treatment.
Activity assays or dynamic light scattering (DLS) can be
employed to monitor the protein.
Initial crystals of the viral protein–ligand complex in Fig. 11
showed no diffraction. However, when this protein complex
was heated to 310 K for 5–10 min, followed by incubation on
ice and centrifugation with a 0.2 mm ﬁlter, the resulting crys-
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Figure 9
Crystals of the kinase 1 ligand complex routinely diffract to 2–2.3 A ˚ .
Figure 10
Incubation of kinase 3 with ligands at room temperature was critical in
obtaining cocrystals of these complexes.
Figure 11
Crystals of a heat-treated viral protein–ligand complex diffract to 2.8 A ˚ .
The addition of 0.1% -octylglucoside to the protein solution was
required to grow crystals of some of these complexes.
Figure 7
Progesterone receptor LBD. Cocrystals of the ligand of interest were
obtained when the protein was initially expressed with a lower afﬁnity
ligand. The ligand of interest was then added in molar excess and
included throughout protein puriﬁcation.
Figure 8
Ligand included throughout the protein puriﬁcation of kinase 1 yielded
pure monomeric protein (b). Puriﬁcation without the ligand resulted in a
mixture of protein, lipids and DNA (a).tals diffracted to 2.8 A ˚ (Wang & Nolte, 2006). The addition of
0.1% -octylglucoside to the protein solution was key to
obtaining crystals of some of these viral protein–ligand
complexes.
4.2. Protein concentration/ligand concentration
Sometimes it is possible to concentrate our protein and then
add the ligand to form the complex. However, if the ligand is
insoluble, it may cause the protein to precipitate when it is at
higher concentrations. It may be necessary to add dilute ligand
to diluted protein to achieve good ligand binding with these
very insoluble compounds. Kinase 4 had to be diluted to
1m gm l
1 and then complexed with dilute ligand at a 1:3
protein:ligand ratio to achieve a stable complex that yielded
well diffracting crystals (Fig. 12). The majority of these
complex cocrystals were grown by cross-seeding using apo
crystals.
Examples have been presented showing the effects of
temperature, protein concentration, the use of additives and
ligand concentration on the formation of protein–ligand
complexes with insoluble compounds. However, there are
additional ways to tackle the problem of insoluble ligands:
homogenize the powdered with a small pestle, mix the ligand
with tiny beads and vortex or sonicate to homogenize the
powder and soak the crystal in cryoprotectant ﬁrst before
adding the ligand.
4.3. Ligand exchange prior to cocrystallization
What if the protein already has a natural ligand in the
ligand-binding pocket (Fig. 13)? How do we obtain cocrystals
of a protein–inhibitor complex?
Generation of cocrystal structures with new ligands has
proven to be challenging for some of the nuclear receptors,
primarily owing to the inability of synthetic ligands to displace
the native phospholipids. After many trials, a protocol was
developed that enhanced the displacement of native phos-
pholipids in nuclear receptor 1 by our synthetic ligands and
accelerated the determination of several ligand-complex
structures.
The synthetic ligand is dissolved in dimethyl sulfoxide
(DMSO) and mixed with phospholipid. This is lyophilized,
dissolved in the protein buffer (liposome suspension) and
complexed with the protein for 1–2 weeks at 277 K.
Displacement of the native phospholipid by the synthetic
compound is followed by mass spectrometry. The new
complex is then puriﬁed by gel-ﬁltration chromatography. The
liposome-treated protein resulted in a reproducible system
routinely giving crystals that diffracted to 2 A ˚ (Fig. 14) for
nuclear receptor 1.
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Figure 12
A protein concentration of 1 mg ml
1 during complex formation and
cross-seeding were critical to obtaining cocrystals of the kinase 4
complexes.
Figure 13
Nuclear receptor 1 with bound natural ligand.
Figure 14
Crystals of the liposome-treated nuclear receptor 1 diffracted to 2 A ˚ .4.4. Cross-seeding
Apo crystals of kinase 5 were easily reproduced, but
growing crystals of the ligand complexes proved difﬁcult. Apo
crystals were used for cross-seeding into Hampton Research
Crystal Screen to ﬁnd initial crystallization conditions for the
ligand complexes. Crystal Screen reagent 28 gave the best
results and was optimized. All of the subsequent cocrystals
were grown by cross-seeding with either apo crystals or crys-
tals of other ligand complexes into this reagent (Fig. 15).
4.5. Real time in situ competition crystallization (RTISCC)
Some proteins require the presence of a ligand during
expression to obtain sufﬁcient quantities of stable protein for
crystallization trials. In some cases, the ligand used during
protein expression is not the ligand of choice for structural
studies. In RTISCC, the ligand of interest is added to the
crystallization drop to compete out the ﬁrst ligand used during
expression (Fig. 16).
4.6. Use of a limited additive screen
It is not uncommon to have ﬁnite quantities of ligands of
interest for cocrystallization studies, thereby limiting the
experiments that can be performed. To address this problem,
Lisa Shewchuk developed a limited additive screen that could
be used in such instances. It is widely used in our laboratory
for optimizing crystals and improving ligand solubility. Our
initial additive screens use these reagents at a 5% concen-
tration where the additive is added directly to the precipitating
reagent. In other cases, these additives have been mixed with
the ligand to improve its solubility.
5. Soaking ligands into existing crystals
Soaking crystals with ligands is often the method of choice to
obtain crystals of protein–ligand complexes owing to the ease
of the method. However, there are several factors to consider.
The crystals may be fragile and soaking in a stabilization
buffer or cross-linking may be required. The soaking time and
inhibitor concentration need to be optimized, as many protein
crystals are sensitive to the solvents used to dissolve the
ligands. Additives may be required to achieve effective ligand
binding during the soak time and/or during the subsequent
cryoprotectant exchange. Finally, you may have cocrystals of
one ligand complex and need to exchange the original ligand
with a different ligand (replacement soaking; Skarzynski &
Thorpe, 2006). The FAST fragment-based screening devel-
oped by Structural Genomix Pharmaceuticals is an example of
a high-throughput soaking-type system that has been quite
successful (Burley, 2004).
Although soaking ligands into crystals may be the method
of choice for a particular protein, it is preferable to validate
the soaking system with cocrystallization experiments when
possible. The full range of conformational changes may not be
seen in instances where the ligand has been soaked into the
crystal. However, in the case of cyclin A–cdk2 crystals, the
cyclin A restricts movement of the cdk2 and soaking in this
system is a valid approach.
5.1. Stabilization of crystals/use of an additive during the
soak
Crystals are often put into ‘stabilization’ buffers before they
are immersed in the ligand solution. These buffers may
contain increased concentrations of the precipitant(s) and a
stepwise/gradual increase in reagent concentration or the
introduction of a cryoprotectant may be required so that the
crystals are not damaged.
Another option for stabilizing crystals is cross-linking with
glutaraldehyde. This has been our method of choice with the
cyclinA–cdk2 crystals that we routinely use as a surrogate
kinase for projects where there is no protein available (Hassell
et al., 1998). These crystals are large and fairly sensitive to
inhibitor soaks and cryoprotectant exchange. The method of
Lusty (1999) using 25% glutaraldehyde in a microbridge for
varied periods of time has worked quite well with this system.
We routinely cross-link these crystals with 5 ml of 25%
glutaraldhyde in a microbridge at 277 K for 30 min, but have
found that these parameters vary greatly depending on the
protein (5 min–18 h). We improved our success rate of soaks
approximately twofold to threefold when this cross-linking
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Figure 15
Crystals of the kinase 5 ligand complexes were obtained by cross-seeding.
Figure 16
Real-time in situ competition crystallization (RTISCC). The ligand of
interest competes out the original ligand used during protein expression.procedure was employed. We also found that the use of PEG
400 increased our success rate with large ligands. The inhibitor
is mixed with 50% PEG 400 in a 1:1 ratio. 1 ml of this mixture is
then added to the cross-linked cyclinA–cdk2 crystals (Fig. 17).
Although PEG 400 has been useful for soaking large ligands
into the cyclinA–cdk2 crystals, there are a variety of reagents
that have proved useful in other systems, including Jeffamines,
sugars, methylpentanediol (MPD) and a variety of PEGS. We
often use some of the reagents in the limited additive screen in
Table 1 to improve ligand solubility. This can be accomplished
in several ways. The additive may be added directly to the
precipitating reagent in the well and thoroughly mixed.
Subsequently, the ligand is added to a drop of this additive/
precipitating reagent mixture in a 1:1 ratio and then added to
the protein drop. Alternatively, the ligand may be mixed with
the additive and then added to the protein drop. The exact
ratios of additive:ligand:precipitating reagent need to be
optimized, as this can vary greatly depending on the type of
ligand.
In protease 1, cocrystallizations yielded very few protein–
ligand complexes, so a soaking strategy was devised. Since the
apo crystals were rather fragile and the ligands were quite
insoluble, an additive was needed that stabilized the crystal
and improved the ligand solubility. Xylitol was added to the
precipitating solution to a ﬁnal concentration of 2–5%. 1 ml
of this mixture was added to the protein drop to stabilize the
crystals (15–60 min). Next, the inhibitor was added to the
additive plus precipitating reagent mix (2–5 ml ligand plus
500 ml precipitating reagent). 1 ml of this ligand mixture was
then added to the crystals (Fig. 18). This procedure was the
only method that led to solution of structures of the protease–
ligand complexes.
5.2. Soaking time/ligand concentration
The previous example showed crystals of cyclinA–cdk2 that
were sensitive to handling where cross-linking and the use of
an additive were critical for successful ligand soaks. However,
in cdk2, a second approach of diluting the inhibitor and using
longer incubation times worked well in obtaining inhibitor
complexes. 1–3 mlo fa5 0 m M stock inhibitor solution was
added to 500 ml well reservoir. 1 ml of this diluted ligand was
then added to a 4–5 ml drop containing the cdk2 crystals
(Fig. 19). Incubation times ranged from several days to 2–3
months.
5.3. Ligand exchange in crystals
There are instances where it is easy to grow crystals that
contain a natural ligand or cocrystals with one inhibitor, but
not with a new ligand or template. In this case, the new ligand
of interest may be soaked into the existing cocrystals, substi-
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Figure 17
Cross-linking with glutaraldehyde and the use of PEG 400 with large
ligands improved the success rate for soaks in the cyclinA–cdk2 system.
Figure 18
Protease 1. The use of xylitol during the soaking stabilized the crystal and
improved the solubility of the ligands. If the ligand was not mixed in the
xylitol plus precipitating mixture, the efﬁciency of obtaining protein–
ligand complexes greatly decreased.
Table 1
Limited additive screen (Lisa Shewchuk) used to improve crystal quality
and ligand solubility.
1 0.10 M MgCl2
2 0.15 M CaCl2
3 1.0 M NaCl
4 25% Jeffamine T403
5 25% Jeffamine M600
6 20% Jeffamine M89
7 25% ethylene glycol
8 25% 1,6-hexanediol
9 20% glucose
10 1.0 M guanidine hydrochloride
11 35% dioxane
12 1.0 M imidazole pH 6.5
13 25% tert-butanol
14 25% MPD
15 0.10 M MnCl2
16 10 mM ZnCl2
17 0.1% TFA
18 0.14 M -mercaptoethanol
19 25% 1,2-propanediol
20 25% PEG 10K
21 25% PEG 400
22 0.10 M triethylamine (TEA)
23 0.10 M spermidine
24 0.25 M argininetuting it for the original compound. When performing this
‘replacement soaking’ (Skarzynski & Thorpe, 2006), one must
consider the binding constant of the new ligand. It may be
difﬁcult to introduce a new lower afﬁnity ligand into the
system and substitute it for a much higher afﬁnity ligand that is
already bound to the protein. The success of the ligand
replacement can be seen when the electron-density map is
calculated.
6. Conclusions
There are a wide variety of techniques available to the
investigator for obtaining protein–ligand complexes. These
include adding ligands during protein expression to obtain
soluble protein, addition of the ligand during protein puriﬁ-
cation, cocrystallization of the ligand with the puriﬁed protein
and soaking ligands into crystals. It is reasonable to start by
soaking the ligands into crystals as this is the easiest method or
to try cocrystallizing the ligand with the puriﬁed protein. If
these are not successful, further optimization of the protein
expression and puriﬁcation may be necessary.
The authors would like to thank Wendy White, Gregg Waitt,
Craig Wagner and Jon Williams for providing critical mass-
spectrometry support for our protein characterization. AMH
wishes to thank the organizers of the 2006 CCP4 Study
Weekend for the invitation to present this work.
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Figure 19
Inhibitor soaks of cdk2 gave crystals that diffracted to 2A ˚ . Dilute
inhibitor concentrations coupled with long incubation times gave the best
complexes.